Loading...
XNASDRRX
Market cap26mUSD
Jan 17, Last price  
0.85USD
1D
2.15%
1Q
-35.61%
Jan 2017
-36.57%
Name

DURECT Corp

Chart & Performance

D1W1MN
XNAS:DRRX chart
P/E
—
P/S
3.09
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
10.66%
Rev. gr., 5y
-14.37%
Revenues
9m
-55.67%
13,853,00028,571,00021,894,00030,675,00025,957,00024,293,00031,591,00033,487,00053,070,00015,326,00019,401,00019,124,00014,025,00049,170,00018,564,00029,564,00030,111,00013,977,00019,283,0008,548,000
Net income
-28m
L-22.37%
-27,637,000-18,128,000-33,327,000-24,339,000-45,051,000-30,715,000-22,898,000-18,765,00016,200,000-21,452,000-22,110,000-22,663,000-34,509,000-3,695,000-25,322,000-22,788,000-2,522,000-38,125,000-35,584,000-27,624,000
CFO
-34m
L+30.95%
-22,208,000-7,211,000-9,479,000-18,295,000-9,434,000-20,894,0007,763,000-17,386,000-13,448,000-15,448,000-14,209,000-20,555,000-27,293,000-1,343,000-19,750,00011,101,000-38,704,000-37,311,000-26,280,000-34,414,000
Earnings
Mar 25, 2025

Profile

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine up to days of in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Santen Pharmaceutical Co., Ltd. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.
URL
https://www.durect.com/
IPO date
Sep 28, 2000
Employees
72
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
8,548
-55.67%
19,283
37.96%
Cost of revenue
31,068
38,450
Unusual Expense (Income)
NOPBT
(22,520)
(19,167)
NOPBT Margin
Operating Taxes
251
Tax Rate
NOPAT
(22,520)
(19,418)
Net income
(27,624)
-22.37%
(35,584)
-6.66%
Dividends
Dividend yield
Proceeds from repurchase of equity
1,564
84
BB yield
-10.00%
-0.11%
Debt
Debt current
19,425
7,107
Long-term debt
6,785
18,247
Deferred revenue
Other long-term liabilities
693
851
Net debt
(3,620)
(18,279)
Cash flow
Cash from operating activities
(34,414)
(26,280)
CAPEX
(52)
(111)
Cash from investing activities
(1,166)
19,836
Cash from financing activities
20,497
83
FCF
(24,460)
(14,157)
Balance
Cash
29,680
43,483
Long term investments
150
150
Excess cash
29,403
42,669
Stockholders' equity
(588,997)
(561,372)
Invested Capital
626,600
610,470
ROIC
ROCE
EV
Common stock shares outstanding
26,520
22,777
Price
0.59
-82.95%
3.46
250.95%
Market cap
15,647
-80.15%
78,808
255.19%
EV
12,027
60,529
EBITDA
(22,489)
(19,048)
EV/EBITDA
Interest
2,792
2,399
Interest/NOPBT